Comparative Pharmacology
Head-to-head clinical analysis: BAXDELA versus FACTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAXDELA versus FACTIVE.
BAXDELA vs FACTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Oral: 450 mg (as single tablet) twice daily for 5 days. Intravenous: 450 mg once daily (over 3 hours) or 300 mg twice daily (over 1 hour) for 5 days.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours in healthy adults; may be prolonged in patients with renal impairment (up to 20 hours in severe renal impairment).
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Renal (approximately 65% of dose as unchanged drug) and fecal (approximately 20% as metabolites and unchanged drug). Biliary excretion is minimal.
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic